Meeting
2014 Genitourinary Cancers Symposium
Phase I trial of the investigational aurora A kinase (AAK) inhibitor MLN8237 (alisertib) in combination with docetaxel (DTX) in patients (pts) with advanced solid tumors, including castration-resistant prostate cancer (CRPC).
Authors
John Sarantopoulos
Institute for Drug Development, The University of Texas Health Science Center at San Antonio, San Antonio, TX
John Sarantopoulos , Noah M. Hahn , Celestia S. Higano , E. Jane Leonard , Bin Zhang , Xiaofei Zhou , Claudio Dansky Ullmann , Julie Nicole Graff
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate, Penile, Urethral, and Testicular Cancers, and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT01094288
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 217)
DOI
10.1200/jco.2014.32.4_suppl.217
Abstract #
217
Poster Bd #
B13
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase I study of the combination of alisertib (MLN8237) and gemcitabine in advanced solid tumors.
First Author: Jasmine Huynh
Poster
2023 ASCO Annual Meeting
Sudocetaxel zendusortide (TH1902), a novel sortilin-receptor (SORT1)-targeting peptide-drug-conjugate (PDC) in patients (pts) with advanced solid tumors: Results from part 1 (dose-escalation) of a phase 1, open-label study.
First Author: Funda Meric-Bernstam
Poster
2023 ASCO Annual Meeting
First-in-human phase 1 dose escalation study of the KAT6 inhibitor PF-07248144 in patients with advanced solid tumors.
First Author: David Sommerhalder
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase 1 study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in patients (pts) with advanced solid tumors including colorectal cancer: Updated dose-escalation part.
First Author: Shunsuke Kondo